Tacrolimus Clinical Trials
52 recruitingDrug
Phase 235Phase 111Phase 37Phase 44Not Applicable1Early Phase 11
Showing 1–20 of 52 trials
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting
Phase 1Phase 2
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Hematopoietic and Lymphoid System Neoplasm
M.D. Anderson Cancer Center25 enrolled1 locationNCT04022239
Recruiting
Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Rheumatic disease
NYU Langone Health80 enrolled1 locationNCT07138898
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 1
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia
OHSU Knight Cancer Institute40 enrolled1 locationNCT07548983
Recruiting
Phase 1
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Acute Myeloid LeukemiaMyelodysplastic SyndromeGraft-Versus-Host Disease
City of Hope Medical Center15 enrolled1 locationNCT06996119
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled102 locationsNCT07204275
Recruiting
Phase 2
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+3 more
City of Hope Medical Center35 enrolled1 locationNCT06815003
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288
Recruiting
Phase 2Phase 3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Kidney Transplant Rejection
Sanofi526 enrolled26 locationsNCT07412470
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Biogen180 enrolled103 locationsNCT06962800
Recruiting
Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Sickle Cell DiseaseThalassemiaThalassemia (beta)
Memorial Sloan Kettering Cancer Center24 enrolled6 locationsNCT05736419
Recruiting
Phase 2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2
Allo HSCT for High Risk Hemoglobinopathies
Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting
Phase 1
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center15 enrolled1 locationNCT06287944
Recruiting
Early Phase 1
Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
Lung Transplant; Complications
Vanderbilt University Medical Center48 enrolled1 locationNCT04469842
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Acute Lymphoblastic LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+5 more
Memorial Sloan Kettering Cancer Center71 enrolled1 locationNCT07566377